Cognitive impairment and dementia in Parkinson's disease
Identifieur interne : 000442 ( Main/Corpus ); précédent : 000441; suivant : 000443Cognitive impairment and dementia in Parkinson's disease
Auteurs : Karen MarderSource :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
Abstract
Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22787
Links to Exploration step
ISTEX:E2EC132AB236CE6376DC1C2614B3C1534B66B8DBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognitive impairment and dementia in Parkinson's disease</title><author><name sortKey="Marder, Karen" sort="Marder, Karen" uniqKey="Marder K" first="Karen" last="Marder">Karen Marder</name><affiliation><mods:affiliation>Departments of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Sergievsky Center, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E2EC132AB236CE6376DC1C2614B3C1534B66B8DB</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22787</idno><idno type="url">https://api.istex.fr/document/E2EC132AB236CE6376DC1C2614B3C1534B66B8DB/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000442</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment and dementia in Parkinson's disease</title><author><name sortKey="Marder, Karen" sort="Marder, Karen" uniqKey="Marder K" first="Karen" last="Marder">Karen Marder</name><affiliation><mods:affiliation>Departments of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychiatry, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Sergievsky Center, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S110">S110</biblScope><biblScope unit="page" to="S116">S116</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E2EC132AB236CE6376DC1C2614B3C1534B66B8DB</idno><idno type="DOI">10.1002/mds.22787</idno><idno type="ArticleID">MDS22787</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>cognitive impairment</term><term>dementia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Karen Marder MD, MPH</name><affiliations><json:string>Departments of Neurology, Columbia University, New York, New York, USA</json:string><json:string>Department of Psychiatry, Columbia University, New York, New York, USA</json:string><json:string>Sergievsky Center, Columbia University, New York, New York, USA</json:string><json:string>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dementia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognitive impairment</value></json:item></subject><articleId><json:string>MDS22787</json:string></articleId><language><json:string>eng</json:string></language><abstract>Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>5.905</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>560</abstractCharCount><pdfWordCount>4993</pdfWordCount><pdfCharCount>32406</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>76</abstractWordCount></qualityIndicators><title>Cognitive impairment and dementia in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>7</total><last>S116</last><first>S110</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><author><json:item><name>Fahn Stanley MD</name></json:item><json:item><name>Marder Karen MD</name></json:item><json:item><name>Côté Lucien MD</name></json:item><json:item><name>Reich Stephen G. MD</name></json:item></author><subject><json:item><value>New Developments in Testing, Diagnosis and Treatment of PD</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22787</json:string></doi><id>E2EC132AB236CE6376DC1C2614B3C1534B66B8DB</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E2EC132AB236CE6376DC1C2614B3C1534B66B8DB/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E2EC132AB236CE6376DC1C2614B3C1534B66B8DB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E2EC132AB236CE6376DC1C2614B3C1534B66B8DB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cognitive impairment and dementia in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>Parkinson's Disease Foundation - No. R01 NS36630; No. UL1 RR024156;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cognitive impairment and dementia in Parkinson's disease</title><author><persName><forename type="first">Karen</forename><surname>Marder</surname></persName><roleName type="degree">MD, MPH</roleName><note type="correspondence"><p>Correspondence: 630 W. 168th St., Unit 16, New York, NY 10032</p></note><affiliation>Departments of Neurology, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Psychiatry, Columbia University, New York, New York, USA</affiliation><affiliation>Sergievsky Center, Columbia University, New York, New York, USA</affiliation><affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S110">S110</biblScope><biblScope unit="page" to="S116">S116</biblScope></imprint></monogr><idno type="istex">E2EC132AB236CE6376DC1C2614B3C1534B66B8DB</idno><idno type="DOI">10.1002/mds.22787</idno><idno type="ArticleID">MDS22787</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>dementia</term></item><item><term>cognitive impairment</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>New Developments in Testing, Diagnosis and Treatment of PD</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-12-08">Received</change><change when="2009-08-21">Registration</change><change when="2010">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E2EC132AB236CE6376DC1C2614B3C1534B66B8DB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="5"><doi origin="wiley" registered="yes">10.1002/mds.v25.1s</doi><titleGroup><title type="specialIssueTitle">Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">S1</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Fahn</givenNames><familyName>Stanley</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Marder</givenNames><familyName>Karen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Côté</givenNames><familyName>Lucien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped4" creatorRole="sponsoringEditor"><personName><givenNames>Reich</givenNames><familyName>Stephen G.</familyName><degrees>MD</degrees></personName></creator></creators><coverDate startDate="2010">2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="21" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22787</doi><idGroup><id type="unit" value="MDS22787"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">New Developments in Testing, Diagnosis and Treatment of PD</title><title type="tocHeading1">New Developments in Testing, Diagnosis and Treatment of PD</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-12-08"></event><event type="manuscriptRevised" date="2008-09-02"></event><event type="manuscriptAccepted" date="2009-08-21"></event><event type="firstOnline" date="2010-02-25"></event><event type="publishedOnlineFinalForm" date="2010-02-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S110</numbering><numbering type="pageLast">S116</numbering></numberingGroup><correspondenceTo>630 W. 168th St., Unit 16, New York, NY 10032</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22787.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="104"></count><count type="wordTotal" number="4897"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cognitive impairment and dementia in Parkinson's disease<link href="#fn1"></link></title><title type="short" xml:lang="en">Cognitive Impairment and Dementia in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3 #af4" corresponding="yes"><personName><givenNames>Karen</givenNames><familyName>Marder</familyName><degrees>MD, MPH</degrees></personName><contactDetails><email>ksm1@columbia.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Psychiatry, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Sergievsky Center, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">dementia</keyword><keyword xml:id="kwd3">cognitive impairment</keyword></keywordGroup><fundingInfo><fundingAgency>Parkinson's Disease Foundation</fundingAgency><fundingNumber>R01 NS36630</fundingNumber><fundingNumber>UL1 RR024156</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cognitive impairment and dementia in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cognitive Impairment and Dementia in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cognitive impairment and dementia in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Karen</namePart><namePart type="family">Marder</namePart><namePart type="termsOfAddress">MD, MPH</namePart><affiliation>Departments of Neurology, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Psychiatry, Columbia University, New York, New York, USA</affiliation><affiliation>Sergievsky Center, Columbia University, New York, New York, USA</affiliation><affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York, USA</affiliation><description>Correspondence: 630 W. 168th St., Unit 16, New York, NY 10032</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010</dateIssued><dateCaptured encoding="w3cdtf">2007-12-08</dateCaptured><dateValid encoding="w3cdtf">2009-08-21</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">104</extent><extent unit="words">4897</extent></physicalDescription><abstract lang="en">Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">Parkinson's Disease Foundation - No. R01 NS36630; No. UL1 RR024156; </note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>dementia</topic><topic>cognitive impairment</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Fahn</namePart><namePart type="family">Stanley</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Marder</namePart><namePart type="family">Karen</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Côté</namePart><namePart type="family">Lucien</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Reich</namePart><namePart type="family">Stephen G.</namePart><namePart type="termsOfAddress">MD</namePart></name><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>New Developments in Testing, Diagnosis and Treatment of PD</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="title"><title>Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><extent unit="pages"><start>S110</start><end>S116</end><total>7</total></extent></part></relatedItem><identifier type="istex">E2EC132AB236CE6376DC1C2614B3C1534B66B8DB</identifier><identifier type="DOI">10.1002/mds.22787</identifier><identifier type="ArticleID">MDS22787</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000442 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000442 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:E2EC132AB236CE6376DC1C2614B3C1534B66B8DB
|texte= Cognitive impairment and dementia in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |